Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers August 19, 2018
Pharmacy Choice - News - Pharmaceutical Development - August 19, 2018

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

8/19/18 - FDA approves Teva's generic of Mylan's EpiPen [Jerusalem Post (Israel)]
The US Food and Drug Administration has approved Teva Pharmaceutical Industries Ltd. s generic version of Mylan NV s life-saving allergy injection, EpiPen, at a time when regulators are looking to lower healthcare costs. There has also been a shortage of EpiPen in North America, Europe and Canada since earlier this year due to manufacturing d
8/18/18 - ActiGraph Announces New Scientific Affairs and Data Management Division [T-break Tech (Middle East)]
Guided by the novel endpoint development framework released by the Clinical Trials Transformation Initiative in 2017, ActiGraphs Scientific Affairs and Data Management division, headed by Director Tyler Guthrie, will facilitate joint research and development projects involving corporate partners and subject matter experts from within the...
8/18/18 - Albumin (As Excipient) Market to Reach US$ 1200 Mn by 2019
Albany, NY 08/18/2018 Global Albumin Market Snapshots. The global albumin market was valued at US$ 750 Mn in 2017 and is anticipated to reach US$ 1200 Mn by 2026 at a CAGR of over 5.0% from 2018 to 2026. For instance, in May 2017, China's Food and Drug Administration granted approval to clinical trials of human blood albumin produced from
8/18/18 - Army Seeks Tick-Borne Encephalitis Vaccine Development
The U.S. Army Medical Research Acquisition Activity has issued a sources sought notice for the development of tick-borne encephalitis vaccine for use by U.S. service members. Excerpts of the notice state: The vaccine must be European Medicines Agency approved, and shall achieve U.S. Food and Drug Administration licensure. For more information about
8/18/18 - Evotec tapped for preclinical studies of BioTherapeutics lead candidate [Tehran Times (Iran)]
Mario Polywka, COO of the preclinical contract research organization Evotec, said in a press release, Our INDiGO platform reduces time and cost while consistently producing a quality data package for clinical trial agreements and investigational new drug filings. Mark Bamberger, CSO of Stealth stated, Our team at Stealth evaluated all options to he
8/18/18 - Faso Highlights FDA Approval of Generic EpiPen Auto-Injector
Rep. Faso had written to FDA Commissioner Dr. At the time, the FDA had just added epinephrine auto-injectors to the FDA' s list of existing drug shortages. I'm glad to see the FDA approve additional effective and safe devices that will lower costs for consumers and expand access. "
8/18/18 - FDA Clears SPR Therapeutics Non-opioid SPRINT endura and extensa Peripheral Nerve Stimulation Systems for Pain Management [Tehran Times (Iran)]
SPR Therapeutics, Inc., a leader in neurostimulation technology for pain, today announced that the U.S. Food and Drug Administration has cleared its SPRINTendura and extensa Peripheral Nerve Stimulation Systems. With the ease of use and dual lead capabilities weve built into the SPRINT System we look forward to advancing the early use of neurostimu
8/18/18 - FDA gives green light to study of cholangiocarcinoma drug [Tehran Times (Iran)]
Sirnaomics, Inc., a biopharmaceutical company in discovery and development of RNAi therapeutics, announces that the U.S. Food and Drug Administration has approved the companys first oncology IND application. Although it is more common in Asia, its incidence in Europe and North America has increased significantly in recent decades. In 2017, STP705 w
8/18/18 - KALYDECO approved as first CF drug in children under 24 months [Syrian Arab News Agency]
Vertex Pharmaceuticals Incorporated has announced the U.S. Food and Drug Administration approved KALYDECO to include use in children with cystic fibrosis ages 12 to.
8/18/18 - Mateon Therapeutics Receives Notice of Partial Clinical Hold for OX1222 Study [T-break Tech (Middle East)]
Mateon Therapeutics, Inc., a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, today announced that the U.S. Food and Drug Administration placed a partial clinical hold on Study OX1222 during a telephone conversation held with the Company on August 16, 2018. OX1222 is the Companys clinical
8/18/18 - Motif Bio to Present Iclaprim Data at ESCMID/ASM Conference [Syrian Arab News Agency]
-Motif Bio plc, a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that iclaprim data will be presented at the upcoming European Society of Clinical Microbiology and Infectious Diseases/ American Society For Microbiology Conference on Drug Development to Meet the Challenge of Antimicrobial...
8/18/18 - Neurocrine Biosciences to Present Data on INGREZZA (valbenazine) and Opicapone at the 2018 World Congress on Parkinson`s Disease and Related Disorders [Sport360]
Neurocrine Biosciences, Inc. today announced it will present data from its movement disorders programs, including additional long-term results for INGREZZA capsules, the first U.S. Food and Drug Administration approved treatment for adults with tardive dyskinesia, and data analyses from a Phase III study on opicapone, an investigational treatment f
8/18/18 - Novocure and US Oncology Research Announce Collaboration [Sudan Tribune]
Collaboration research agreements can go a long way to expedite clinical trials which, in turn, could reduce research and development costs, or share them. Novocure and US Oncology Research said in a joint press release on Wednesday a collaboration for Panova-3, a Phase 3 trial. Daniel D. Von Hoff, principal investigator for Panova-3 and chief scie
8/18/18 - Positive Results for New Osteoarthritis Drug [Sudan Tribune]
Two pharmaceutical companies have announced positive results from a Phase 3 study of an experimental non-opioid pain reliever that has a history of safety concerns. Teva and Regeneron are jointly developing fasinumab as a treatment for chronic pain from osteoarthritis of the knee and hip. "We are encouraged by these data and look forward to advanc
8/18/18 - Promis Neurosciences has 79 per cent upside, says Mackie Research [Sport360]
After publishing its second quarter results, Canadian biotech company Promis Neurosciences got a target price reduction from Andr Uddin of Mackie Research Capital, who now sees a longer timeline for the potential licensing of the companys Alzheimer treatment drug, which PMN expects still have its first clinical trial by the second half of 2019..
8/18/18 - Regeneron sees rejection one day, US FDA approval the next [T-break Tech (Middle East)]
The US FDA has approved Regenerons latest indication for eye drug Eylea, just four days after rejecting the sBLA in a complete response letter. Regeneron Pharmaceuticals announced approval of its supplemental biologics license application for Eylea injection, with a 12- week dosing schedule, earlier today. The approval comes just days after the fir
8/18/18 - Sirnaomics cleared to start first trial of RNAi lead in cancer [T-break Tech (Middle East)]
Sirnaomics founder and CEO Patrick Lu, Ph.D., said the patisiran approval validates the RNAi class of therapeutics and it is our belief that the industry will see great enthusiasm and expanded discovery and development of novel RNAi therapeutics for many disease applications. The Gaithersburg, Maryland- based biotech has been working on RNAi therap
8/18/18 - ViiV Healthcare announces positive results from phase III ATLAS study of long-acting, injectable 2DR for HIV treatment [Tehran Times (Iran)]
ViiV Healthcare announced positive headline results from its global, phase III ATLAS study of a long-acting, injectable two-drug regimen for the treatment of HIV. ATLAS was designed to establish if HIV-1-infected adult participants who had maintained viral suppression for at least six months, on a daily oral regimen comprised of two nucleoside reve
8/18/18 - White & Case Advises SYNLAB on Acquisition of Leading Finnish Laboratory Services Provider
Global law firm White& Case LLP has advised SYNLAB on the acquisition of Yhtyneet Medix Laboratoriot Oy, Finland's leading private laboratory company, from Medix Laboratoriot Oy and Yhtyneet Laboratoriot Oy. SYNLAB Group, the European market leader in medical diagnostic services, offers the full range of innovative and reliable medical diagnostics
8/17/18 - 'Global Biosimulation Market Worth Over $1.2 Billion in 2017' Says Visiongain Report
Visiongain, a independent media company, issued the following news release:. Visiongain's new report Biosimulation World Market 2017-2027: Revenue Prospects by Product, Services, Application (Drug Development, Preclinical Testing, ADME/Tox, PK/PD, Clinical Trials, Drug Discovery, End User (Pharmaceutical and Biotechnology Companies, CROs, Academic&
8/17/18 - A1M Pharmas drug candidate ROSgard protects against acute kidney damage in American preclinical study
A1M Pharma announces that the company's drug candidate ROSgard shows strong protection against acute renal injury in a pre-clinical study conducted in the United States together with Indiana University. The pre-clinical AKI study in the United States was conducted with a different animal species, and with a partially different methodology compared
8/17/18 - Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Guidance for Industry: Controlled Correspondence Related to Generic Drug Development
Agency: " Food and Drug Administration, HHS." SUMMARY: The Food and Drug Administration is announcing that a proposed collection of information has been submitted to the Office of Management and Budget for review and clearance under the Paperwork Reduction Act of 1995.. FOR FURTHER INFORMATION CONTACT: Domini Bean, Office of Operations, Food and Dr
8/17/18 - Akari Announces First Quarter 2018 Financial Results and Update on its Growing Pipeline of Phase II and Phase III Clinical Trials
Akari Therapeutics, a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, today announced its financial results for the first quarter ended March 31, 2018 and highlights its pipeline of Phase II and Phase III clinical trials.
8/17/18 - Alnylam Announces Alignment on Value-Based Agreements with Leading Health Insurers and Launches Comprehensive Patient Support Services for ONPATTRO
CAMBRIDGE- Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced it has agreed on the structure and key terms of value-based agreements with leading health insurers for ONPATTRO lipid complex injection, a first-of-its-kind RNA interference therapeutic for the treatment of the polyneuropathy of hereditary...
8/17/18 - Alnylam Announces First-Ever FDA Approval of an RNAi Therapeutic, ONPATTRO for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
CAMBRIDGE- Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that the United States Food and Drug Administration approved ONPATTRO lipid complex injection, a first-of-its-kind RNA interference therapeutic, for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement